Skip to main content

Basic Biostatistics for the Clinical Trialist

  • Chapter
  • First Online:
Principles of Anticancer Drug Development

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1796 Accesses

Abstract

The purpose of this chapter is to acquaint the reader with some typically used biostatistical principles and methods in anticancer drug development for summarizing and analyzing data. Understanding and properly interpreting statistics is critically important for drug development. Each stage of development, ranging from preclinical studies to phase III clinical trials, utilizes some form of statistical analysis whether it is as simple as the calculation of a mean or as complex as a longitudinal model with a complicated correlation structure. Proper statistical design and analysis will be critical for making valid inferences and moving to the next phase of research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Since log(A)  −  log(B)  =  log(A/B), then the equation log(A)  −  log(B)  =  0 is equivalent to log(A/B)  =  0. Exponentiation of both sides of the latter leads to the equivalent expression, A/B  =  1.

  2. 2.

    For independent events, A and B, Pr(A and B)  =  Pr(A)  ×  Pr(B). For example, if we assume FTase inhibition and sample type are independent, then from Table 1.3a the probability a sample comprises AML isolates and exhibits FTase inhibition is (57/106)  ×  (88/106)  ≈  0.446. Therefore, out of 106 total samples, we expect 0.446 ´ 106  ≈  47.3 to be AML isolates exhibiting FTase inhibition – assuming independence. The remaining cells in Table 1.3b are derived in a similar manner.

  3. 3.

    In this example, we assume FTase inhibition levels in AML isolates and buccal samples from the same patient are uncorrelated.

  4. 4.

    For a binary variable with success probability p, the variance is equal to p(1  −  p).

  5. 5.

    The terms “multivariable” and “multivariate” are often used interchangeably. Strictly speaking however, a multivariable analysis refers to a statistical model of a single outcome as a function of multiple variables. In contrast, a multivariate analysis refers to the joint modeling of multiple outcomes simultaneously.

  6. 6.

    Let log(p/(1  –  p))  =  x. Then p  =  1/(1  +  ex). For the example in the text, log(p/(1  −  p))  =  −1.4668 so that p  =  1/(1  +  e1.4668)  ≈  0.19.

References

  1. Daniel W. Biostatistics: A Foundation for Analysis in the Health Sciences. Wiley: New York; 8th edition (2004).

    Google Scholar 

  2. Katz MH. Multivariable Analysis: A Practical Guide for Clinicians. Cambridge University Press: Cambridge; 2nd edition (2006).

    Book  Google Scholar 

  3. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, and Karp JE. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007;109(4):1387–94.

    Article  PubMed  CAS  Google Scholar 

  4. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, and Willman CL. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood. 1997;89(9):3323–9.

    PubMed  CAS  Google Scholar 

  5. Rosner B. Fundamentals of Biostatistics. Duxbury Press: Pacific Grove, CA; 6th edition (2005).

    Google Scholar 

  6. Van Belle G, Heagerty P, Fisher L, Lumley T. Biostatistics: A Methodology for the Health Sciences. Wiley-Interscience: New York; 2nd edition (2004).

    Book  Google Scholar 

Suggested Statistical Software

  1. Stata

    Google Scholar 

  2. SPSS

    Google Scholar 

  3. Minitab

    Google Scholar 

  4. SAS

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Elizabeth Garrett-Mayer .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hill, E.G., Garrett-Mayer, E. (2011). Basic Biostatistics for the Clinical Trialist. In: Garrett-Mayer, E. (eds) Principles of Anticancer Drug Development. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7358-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-7358-0_1

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-7357-3

  • Online ISBN: 978-1-4419-7358-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics